2046 related articles for article (PubMed ID: 31456521)
1. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
2. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
4. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
5. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
7. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
8. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
9. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
10. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
11. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.
Vinke JSJ; Heerspink HJL; de Borst MH
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):321-327. PubMed ID: 30958403
[TBL] [Abstract][Full Text] [Related]
16. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Pancholia AK
Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Wanner C; Marx N
Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
